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Background: Most patients with heart failure are diagnosed and managed in primary care, however, underdiagnosis
and undertreatment are common. We assessed whether implementation of a diagnostic-therapeutic strategy improves
functionality, health-related quality of life, and uptake of heart failure medication in primary care.
Methods/Design: A selective screening study followed by a single-blind cluster randomized trial in primary care.
The study population consists of patients aged 65 years or over who presented themselves to the general practitioner
in the previous 12 months with shortness of breath on exertion. Patients already known with established heart failure,
confirmed by echocardiography, are excluded. Diagnostic investigations include history taking, physical examination,
electrocardiography, and serum N-terminal pro B-type natriuretic peptide levels. Only participants with an abnormal
electrocardiogram or an N-terminal pro B-type natriuretic peptide level exceeding the exclusionary cutpoint for non-acute
onset heart failure (> 15 pmol/L (≈ 125 pg/ml)) will undergo open-access echocardiography. The diagnosis of heart failure
(with reduced or preserved ejection fraction) is established by an expert panel consisting of two cardiologists and a
general practitioner, according to the criteria of the European Society of Cardiology guidelines.
Patients with newly established heart failure are allocated to either the ‘care as usual’ group or the ‘intervention’
group. Randomization is at the level of the general practitioner. In the intervention group general practitioners
receive a single half-day training in heart failure management and the use of a structured up-titration scheme. All
participants fill out quality of life questionnaires at baseline and after six months of follow-up. A six-minute walking
test will be performed in patients with heart failure. Information on medication and hospitalization rates is extracted
from the electronic medical files of the general practitioners.
Discussion: This study will provide information on the prevalence of unrecognized heart failure in elderly with
shortness of breath on exertion, and the randomized comparison will reveal whether management based on a half-day
training of general practitioners in the practical application of an up-titration scheme results in improvements in
functionality, health-related quality of life, and uptake of heart failure medication in heart failure patients compared
to care as usual.
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Heart failure (HF) is an emerging epidemic in the eld-
erly, causing high mortality rates, substantial loss in
quality of life, and high healthcare costs [1]. The last two
decades, progress in patient management, including
multiple drug therapies and implantable devices, has im-
proved prognosis of patients with heart failure with re-
duced ejection fraction (HF-REF) [2,3]. Poor compliance
to and insufficient up-titration of evidence-based medi-
cation is a major contributor to hospital (re)admissions
and loss of life years in these patients [4]. Angiotensin
converting enzyme (ACE) inhibitors, angiotensin recep-
tor blockers (ARBs) and beta-blockers did not show a
significant beneficial effect in patients with heart failure
with preserved ejection fraction (HF-PEF) [5], and their
prognosis did not improve over the last years [6]. Cur-
rently, adequate treatment of hypertension and other
comorbidities, control of heart rate in those with concur-
rent atrial fibrillation, and diuretics to control sodium and
water retention are considered important in HF-PEF [4].
The majority of the elderly patients with HF is diag-
nosed and managed in primary care [7]. Unfortunately
however, recognizing HF in the early stage is challen-
ging, and echocardiography is not readily available in
primary care. A diagnosis based on the signs and symp-
toms only, without echocardiography, results in both
false-positive [8,9] and false-negative diagnoses [10].
Moreover, uncertainty about HF diagnosis and fear of
side effects have led to underutilization of ACE-
inhibitors and beta-blockers in patients with HF in pri-
mary care [11,12].
We suspect that especially in older persons presenting
with shortness of breath to the general practitioner
(GP), the prevalence of undetected HF is high. There-
fore, we developed a selective screening strategy, inclu-
ding an open-access outpatient echocardiography facility.
In addition we developed an easy to apply up-titration
scheme for those newly diagnosed with HF-REF and
HF-PEF. Our main objective is to assess whether such
a targeted diagnostic-therapeutic approach improves
current underdiagnosis and undertreatment.
Key objectives
– To determine the prevalence of unrecognized heart
failure (HF-REF, HF-PEF, and isolated right sided heart
failure) in elderly who present themselves with
shortness of breath on exertion to the general
practitioner.
– To examine the effect of treatment guided by a
structured up-titration scheme on functionality,
health-related quality of life, and uptake of heart failure
medication in patients with newly, screen-detected HF.
– To assess the cost-effectiveness of such an intervention.Methods/Design
Study design
Our design consists of two parts. The first part is a se-
lective screening study (case finding) of HF in elderly
with shortness of breath on exertion. The second part is
a single-blind, cluster randomized controlled trial com-
paring an intervention at the level of the GP to improve
treatment uptake with care as usual in those with
screen-detected HF. The intervention consists of a half-
day training in the management of HF, and the practical
application of an up-titration scheme for HF-REF and
HF-PEF separately. See Figure 1 for the study flowchart.
Study population and recruitment
Thirty primary care practices in the Zeist region, located
in the vicinity of the Diakonessenhuis hospital Zeist, the
Netherlands, participate in this study. In this sample of
primary care practices, urban, suburban and rural com-
munities are represented.
The study population consists of persons aged 65 years
or over who in the previous 12 months presented them-
selves to one of the participating GPs with shortness of
breath on exertion (including those known with a pul-
monary disease), irrespective of whether they were sus-
pected of HF or not. Shortness of breath was not
necessarily the main reason for contact. Eligible subjects
are identified from the electronic medical files of the
participating GPs by a single physician (EvR).
Patients already known with an established diagnosis
of HF confirmed by a cardiologist with help of an echo-
cardiography are excluded, as are patients with a life ex-
pectancy shorter than 6 months, and those unable to
give informed consent.
We consider our study sample representative for
elderly aged 65 years or over in the community, since in
the Netherlands all citizens, except those living in a
nursing home or hospice, are registered with a GP,
irrespective of (co)treatment by a specialist.
Randomization and blinding
Random allocation to either management guided by a
structured up-titration scheme (intervention group) or
care as usual (control group) will be executed at the
level of the GP. As a result, patients with HF of one and
the same GP (a cluster) will all be managed according to
the same arm. This approach was taken to reduce the
risk of contamination between patient groups.
Since it is not deemed feasible to keep the GPs in the
care as usual group unaware of the existence of an inter-
vention arm, blinding of the participants is considered
necessary to minimize bias in assessing the outcome pa-
rameters. In addition, the researcher performing the six
minutes walking test is blinded to the patient’s allocation
arm. The risk of observer bias for the other endpoints is
Patients aged 65 years or over 
who presented themselves the 
year before with shortness of 
breath on exertion, selected 
from the GPs ’EMF
Exclusion of those with 
established HF, a life 
expectancy < 6 months, or
not able to sign IC
Diagnostic assessment: history 
taking, physical examination, 
NTproBNP level, electrocardiogram
Participants with abnormal 
electrocardiogram or  
NTproBNP level ≥ 125 pg/ml
Participants with normal 
electrocardiogram and  
NTproBNP level < 125 pg/ml
Echocardiography
Participants in which 
panel ruled out HF 
Participants in which 
panel established HF 
Patients with a  




Patients managed by 
GPs with care as
usual
Figure 1 Flowchart STRETCH – study. GP = general practitioner, EMF = electronic medical file, HF = heart failure, IC = informed consent,
NTproBNP = N-terminal pro B-type natriuretic peptide.
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filled out at home by the participants themselves, and
retrieving information on HF medication and HF related
doctor appointments from the electronic medical files is
not subject to interpretation.
Sample size
The difference in mean distance walked during the six-
minute walking test (6MWT) between the two groups
after six months follow-up will be taken as the primary
outcome. The average distance walked by HF patients
ranges from 242 m (standard deviation 71 m) up to 427
m (standard deviation 100 m), depending on the severity
of HF [13]. Since it was shown that an increase of 50 m
in walking distance indicated a clinically relevant change
[14,15], we consider a mean difference of 50 meters
between groups as the minimal important difference to
show an effect of the intervention.
We used the two-sample t-test power analysis to
examine how many HF patients are needed per group to
demonstrate an effect. With an effect size of 0.6, alphaof 0.05, and beta of 0.2, group sample sizes of two times
45 will be sufficient.
We assume that in a standard general practice with
2400 patients, at least 50 patients aged 65 years or over
will experience shortness of breath during a one-year
period. The prevalence of previously unrecognized HF in
such patients is expected to be around 14% (10.4-17.5%)
[16]. With a participation rate of 50%, a mean number
of 3.5 patients per GP are expected to have newly de-
tected HF (50% HF-REF and 50% HF-PEF). Twenty-six
general practitioners are needed to reach the targeted
number of HF patients. We will include 4 extra practices
to allow for taking clustering into account.
Diagnostic procedures
Participants will be send two health-related quality of life
(HRQoL) questionnaires. They will fill out these ques-
tionnaires before the initial baseline assessment that will
be performed by a trained physician and research nurse
at the outpatient clinic of the Julius Center. If unable to
travel to the study center, participants will be visited at
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tained from all participants.
After signing informed consent, participants receive a
diagnostic work-up scheme. Diagnostic investigations
include history taking, physical examination, an electro-
cardiogram (ECG), and a blood test for N-terminal pro
B-type natriuretic peptide (NTproBNP) levels. For the
assessment of medical history, comorbidities, symp-
toms, and current drug use, a standardised digital
questionnaire will be used. Physical examination in-
cludes height and weight, blood pressure (two read-
ings), pulse, respiratory rate, pulmonary percussion and
auscultation, heart auscultation, palpation of the apex
beat, measurement of the jugular venous pressure, pal-
pation of the liver and inspection for signs of venous
insufficiency.
Blood serum concentrations of NTproBNP will be
analysed with a non-competitive immunoradiometric
assay (Roche, Mannheim, Germany). NTproBNP is con-
sidered elevated if the value exceeds the exclusionary cut
point 15 pmol/L (~125 pg/ml), in line with the ESC
guidelines on HF [17].
A standard 12-lead ECGs will be recorded in supine
position. All ECGs will be analysed by a trained GP with
special expertise in heart failure (FR), according to the
Minnesota coding criteria [18], without knowledge of
the patients’ clinical status.
The ECG is considered abnormal when one of the fol-
lowing is present; atrial fibrillation, sinus tachycardia
(heart rate > 100 beats per minute), left and right bundle
branch block (complete and incomplete), left anterior
and posterior block, left ventricular hypertrophy, patho-
logical Q-waves suspected for previous myocardial in-
farction, P-wave abnormalities compatible with left atrial
enlargement, ST-segment/T-wave abnormalities, or sec-
ond or third degree AV block.
Only participants with an abnormal ECG or an elevated
blood NTproBNP level will undergo additional echocardi-
ography in the outpatient clinic of the Diakonessenhuis
Hospital Zeist. Echocardiography is performed by a single
trained and experienced cardiac sonographer (HvdH)
using a Philips iE33 imaging system, Andover MA,
blinded to the patients’ test results of the diagnostic work-
up. Guidelines of the American Society of Echocardiog-
raphy [19,20] will be followed to assess structural and
functional cardiac properties. The left ventricular ejection
fraction (LVEF) will be assessed quantitatively, or semi-
quantitatively when necessary. Multiple diastolic parame-
ters will be measured, including pulsed-wave Doppler of
the mitral and pulmonary venous inflow and tissue
Doppler imaging of the mitral annulus motion. The ratio
of peak early (E) diastolic filling velocity to peak of atrial
(A) contraction (E/A ratio) will be calculated. The early
diastolic mitral annular velocity (e’) will be determined atthe septal and lateral wall, and the average of both veloci-
ties will be used to calculate the E/e’ ratio.
Participants will register the experienced burden of the
aforementioned investigations on a visual analogue scale
(VAS) (0 = not burdening at all, 10 = extremely burdening).
The participating GPs will receive a first preliminary
conclusion about the presence or absence of HF, based
on all available information from the diagnostic work
up. GPs will be asked to initiate treatment in patients
with HF according to their allocation (intervention or
care as usual). An expert panel consisting of two cardiol-
ogists and a GP will finally establish or exclude HF.
Participants with a newly established diagnosis of HF
will be asked to perform a 6MWT [21], and again after
six months of follow-up. All participants will be asked to
fill out the HRQoL questionnaires again six months after
the diagnostic assessment.
In addition, information about medication, HF related
appointments with the GP, HF related referrals to the
cardiologist, and HF related hospitalization rates will be
extracted from the electronic medical files at the GP’s
office during 12 months of follow-up.
Intervention
Patients with newly diagnosed HF will participate in the
cluster randomize trial, except for those having a poten-
tially treatable cause of their HF; they will immediately
be referred to a cardiologist. All other HF patients will
receive either care as usual or management guided by a
structured up-titration scheme (intervention) by their
own GP.
The GPs randomly allocated to the intervention group
will receive a half-day training in the management of HF
and the practical application of an up-titration scheme
for HF-REF and HF-PEF separately, based on the Dutch
GPs’ heart failure guideline (NHG-standaard Hartfalen
2005) [22], a Dutch equivalent of the recent ESC Guide-
line on heart failure [4].
In patients with newly established HF-REF, the up-
titration scheme will start with a combination of a diur-
etic and an ACE-inhibitor, or in case of intolerance to an
ACE-inhibitor an ARB. In case of acceptable blood pres-
sures, ACE-inhibitors will be further up-titrated until
half of the recommended dose. When patients are in
euvolemic state and there are no contra-indications, GPs
will then start with up-titration of a beta-blocker. The
dosage of the beta-blocker will be increased to either the
maximal recommended dose or the maximal tolerated
dose. After the up-titration period of the beta-blocker,
the GP will try to further increase the dosage of the
ACE-inhibitor up to either the maximal recommended
dose or maximal tolerated dose.
Patients with newly established HF-PEF will receive
optimal blood pressure treatment. An ACE-inhibitor (or
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case of tachycardia such as in atrial fibrillation, the GP
will aim to regulate the heart rate, preferably with a
beta-blocker. A diuretic will also be prescribed if signs
or symptoms of fluid or salt retention are present. See
Figure 2 for a simplified version of the initiation- and
up-titration scheme for HF patients, and Additional file 1
for the full content of the scheme.
The GPs randomly allocated to the control group will
manage patients with a newly screen-detected diagnosis
of HF as they are used to (care as usual). They are ex-
pected to follow the same Dutch heart failure guideline,
however, they will lack the guided up-titration scheme
and will not receive a special training.alternate 1 2
A. HF-REF
B. HF-PEF
Stable patient with p
systolic RR > 100 m
degree AV-block on
Start diuretic
In case of fluid overload a loop,  
otherwise a thiazide diuretic.
Start beta-b
increase each two wee
dose or maximal to
Increase ACE-in
increase each two we






in case of fluid overload.
Figure 2 Simplified version of the treatment scheme for heart failure
failure with preserved ejection fraction, EF = ejection fraction, ACE = angiotens
RR = blood pressure, ECG = electrocardiogram, AV-block = atrioventricular blocReferral to a cardiologist is possible at any stage in this
pragmatic trial. GPs in both groups will receive instruc-
tions about when it is advisable to refer patients for spe-
cialist consultation in line with the guidelines on HF, e.g.
if patients remain symptomatic after the up-titration
phase, in case of complications or adverse effects, and
when a novel treatable cause of HF is suspected.
Outcome measures
Heart failure
An expert panel, consisting of two cardiologists (AL and
ML) and one GP with special expertise in heart failure
(FR) will determine the presence or absence of HF based
on all diagnostic test results. Consensus diagnosis by an3 4
ulse rate > 50/min, 
mHg, and no 2nd/3rd 
 electrocardiography
Start ACE-inhibitor (or ARB)
increase each two weeks to half 
the recommended dose.










Treat hypertension and other  
comorbidities by protocol, lower 
pulse rate in case of tachycardia.
. HF-REF = heart failure with reduced ejection fraction, HF-PEF = heart
in converting enzyme, ARB = angiotensin receptor blocker, min = minute,
k.
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ciently reliable reference standard is lacking, as is the
case for HF [7].
The panel moves along three phases in their decision
making process; part 1 history taking and physical exa-
mination, part 2 adding NTproBNP and ECG, and part
3 adding echocardiography. After part 1 and 2, the panel
expresses their suspicion for the presence of HF in a
percentage (0-100%). With this approach, we can evalu-
ate which investigations add most in reaching the final
decision (set in part 3).
To classify participants as (not) having HF, the panel
will follow the latest criteria of the European Society for
Cardiology [17]. HF is considered present when partici-
pants have suggestive symptoms (typically breathlessness
at rest or on exercise, fatigue, tiredness, ankle swelling)
and signs (typically tachycardia, tachypnea, pulmonary
rales, raised jugular venous pressure, peripheral oedema,
laterally displaced apical beat) in combination with ob-
jective echocardiographic evidence of cardiac dysfunc-
tion at rest. Signs of volume overload could be masked
when diuretics are used for hypertension, and therefore
in participants on diuretics signs of fluid overload are
not mandatory.
Heart failure is further classified in HF-REF, HF-PEF,
or isolated right sided HF. Patients in whom signs and
symptoms of HF are present in combination with a
LVEF ≤ 45%, are classified as having HF-REF. Patients in
whom signs and symptoms of HF are present in combi-
nation with a LVEF > 45% and echocardiographic
evidence of diastolic dysfunction, are classified as having
HF-PEF.
The E/e’ ratio is regarded as a key parameter for asses-
sing diastolic dysfunction; an E/e’ greater than or equal
to 15 is considered abnormal, an E/e’ value between 9
and 14 indeterminate, and an E/e’ less than 9 as normal.
In case the E/e’ is indeterminate, at least two additional
abnormal parameters are needed to establish diastolic
dysfunction [20,23]; an E/A ratio below 0.75 or above
1.5, an E-deceleration time >280 ms, a time difference
between the duration of the atrial reversal velocity and
the late diastolic mitral inflow duration (Ar - A) of more
than 30 ms, a left atrial volume index > 34 ml/m2, a left
ventricular mass indexed by body surface area > 95 g/m2
in women, and > 115 g/m2 in men (according to the
formula of Devereux [24].
A complete assessment of diastolic dysfunction is
not possible in participants with atrial fibrillation. In
such participants an elevated indexed left atrial volume
(≥34 ml/m2) in combination with AF will be consi-
dered sufficient to establish diastolic dysfunction.
To diagnose isolated right-sided HF, patients need to
have signs and symptoms of HF in combination with a
LVEF > 45%, and an increased pulmonary artery pressure(calculated systolic pulmonary artery pressure >40 mmHg),
in the absence of (overt) diastolic dysfunction.
By re-assessment of a random sample of 10% by the
same outcome panel, blinded to the original decision, the
reproducibility of the panel diagnoses will be evaluated.
Functional capacity
For the elderly HF patient exercise intolerance can be
very limiting and of major clinical importance. We chose
the 6MWT for the objective evaluation of submaximal
functional capacity in patients with newly established
HF, because the exercise level is consistent with daily
physical activities [21]. The 6MWT is considered a valid,
easy, well-tolerated, and inexpensive test [25] that mea-
sures the distance that a patient can walk on a flat, hard
surface during 6 minutes. The test will be executed
according to the guidelines of the American Thoracic
Society [21].
Health-related quality of life
The SF-36 [26,27] and EQ-5D [28,29] were chosen as in-
struments to measure general health status of all parti-
cipants. In addition, the scores of the EQ-5D will be
converted to a time trade-off utility score to calculate
quality-adjusted life years for the cost-effectiveness analysis.
The MLHF questionnaire was added as a condition-
specific measurement for HF patients to evaluate the pa-
tients’ perception of the effects of HF on the physical,
socioeconomic and psychological aspects of their life.
All questionnaires are well validated and widely used.
Costs
Relevant cost parameters within and outside the health-
care system will be collected prospectively during a
follow-up period of 12 months. Direct costs within the
health care system will be monitored through the elec-
tronic medical patients files of the GPs, including the
costs of further diagnostic testing, time consumption of
health care workers (i.e. GP contacts, referrals to me-
dical specialists, hospital admissions), and treatment ex-
penses. Costs outside the healthcare system include the
estimation of time-investment and travelling expenses
patients make. As the population under study is older
than 65 years of age, costs of productivity loss will not
be studied. Regarding the standardization of costs, we
will use a uniform costing methodology [30].
Statistical analyses
Prevalence rates of newly established HF-REF, HF-PEF
and isolated right sided HF in our population with short-
ness of breath on exertion will be calculated as propor-
tions with 95% confidence intervals.
Differences in functionality and quality of life after 6
months of follow-up, and uptake of HF medication
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will be compared taking into account potential diffe-
rence of relevant parameters at baseline (ANCOVA), al-
though such differences are expected to be minimal
because of the randomization procedure. This will be
done separately for patients with HF-REF and HF-PEF.
A multilevel approach is used in the analyses to correctTable 1 Baseline characteristics of the 585 participants, divid
Characteristics All Ca
n = 585 n =
General
Mean age in years ± sd 74.1 ± 6.3 73.
Female sex 319 (54.5) 181
MRC dyspnea score ≥ 3 157 (26.8) 97
Cardiovascular comorbidities
Ischemic heart disease 116 (19.8) 70
Prior myocardial infarction 43 (7.4) 27
Prior PCI/CABG 47 (8.0) 29
Vascular comorbidity 351 (60.0) 217
Hypertension 310 (53.0) 196
Hypercholesterolemia 187 (32) 115
Diabetes Mellitus 79 (13.5) 47
Prior stroke or TIA 51 (8.7) 27
Peripheral arterial disease 35 (6.0) 22
Atrial fibrillation 42 (7.2) 33
Non-cardiovascular comorbidities
Cognitive disorders 110 (18.8) 50
Asthma/COPD 323 (55.2) 200
Depression 72 (12.3) 39
Medication
Loop diuretics 55 (9.4) 36
Thiazide diuretics 147 (25.1) 89
ACE-inhibitors 120 (20.5) 70
ARBs 128 (21.9) 83
Beta-blockers 128 (21.9) 79
Digitalis 5 (0.9) 4 (1
Aldosterone antagonists 7 (1.2) 7 (2
Oral anticoagulants 51 (8.7) 37
Antiplatelets 147 (25.1) 84
Statins 179 (30.6) 110
Nitrates 41 (7.0) 26
Calcium channel blockers 76 (13.0) 54
Values are numbers (percentages).
*Intervention = a half-day training in the management of HF and the practical appl
Sd = standard deviation, MRC = medical research council, PCI = percutaneous coro
ischemic attack, COPD = chronic obstructive pulmonary disease, ACE = angiotensin
HF-REF = heart failure with reduced ejection fraction, HF-PEF = heart failure with prfor the fact that we randomized at the level of the GP
and not at the patient level.
The cost-effectiveness of training GPs in the manage-
ment of HF and the practical application of an up-
titration scheme will be evaluated and compared with
care as usual. Cost-effectiveness will be expressed in
terms of costs per quality-adjusted life year gained (cost-ed in the intervention and care as usual group
re as usual Intervention*
351 (60%) n = 234 (40%) p-value
8 ± 6.1 74.4 ± 6.5 0.25
(51.6) 138 (59.0) 0.08
(27.6) 60 (25.6) 0.59
(19.9) 46 (19.7) 0.93
(7.7) 16 (6.8) 0.70
(8.3) 18 (7.7) 0.80
(61.8) 134 (57.3) 0.27
(55.8) 114 (48.7) 0.09
(32.8) 72 (30.8) 0.61
(13.4) 32 (13.7) 0.92
(7.7) 24 (10.3) 0.28
(6.3) 13 (5.6) 0.72
(9.4) 9 (3.8) 0.01
(14.2) 60 (25.6) 0.001
(57.0) 123 (52.6) 0.29
(11.1) 33 (14.1) 0.28
(10.3) 19 (8.1) 0.39
(25.4) 58 (24.8) 0.88
(19.9) 50 (21.4) 0.68
(23.6) 45 (19.2) 0.21
(22.5) 49 (20.9) 0.65
.1) 1 (0.4) 0.36
.0) 0 (0.0) 0.03
(10.5) 14 (6.0) 0.06
(23.9) 63 (26.9) 0.41
(31.3) 69 (29.5) 0.63
(7.4) 15 (6.4) 0.64
(15.4) 22 (9.4) 0.04
ication of an up-titration scheme for HF-REF and HF-PEF.
nary intervention, CABG = coronary artery bypass grafting, TIA = transient
converting enzyme, ARB = angiotensin receptor blocker, HF = heart failure,
eserved ejection fraction.
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lation of the costs and the definition of effects, and these
are subjected to different margins of uncertainty. To as-
sess to what extent the results of the analysis depend on
prior assumptions and choices made, a sensitivity ana-
lysis will be performed conform current Dutch standards
for pharmacoeconomic research [31].
Results of inclusion
Thirty GPs are included in the study, 14 were rando-
mized to the care as usual arm and 16 to the interven-
tion arm. We invited 1,527 elderly patients with shortness
of breath on exertion to participate in the study. Of the in-
vited patients, 77% responded, and eventually 38% was
willing to participate. Reasons named for non-participation
were; expected burden too high (40%), already known to
a cardiologist (24%), other demanding health problems
(15%), not experiencing shortness of breath anymore
(12%), and severe immobility (5%).
Finally, 585 patients signed informed consent and were
included in our study. The mean age of the participants
was 74.1 (SD ±6.3) years. Stratified by age, 57% was aged
between 65 and 74 years, 37% between 75 and 84 years,
and 6% was aged 85 years or over. The percentage females
was 54.5%. Important comorbidities were pulmonary dis-
ease (55.2%), hypertension (53%), hypercholesterolemia
(32%), and ischemic heart disease (20%). The 14 GPs in
the care as usual arm yielded 351 participants, and the 16
GPs of the up-titration arm 234 participants. Baseline
characteristics of included patients divided between both
groups are described in Table 1.
Discussion
The diagnostic part of our study will provide information
on the prevalence rate of previously unrecognized HF in
older community-dwelling persons with shortness of
breath on exertion. The cluster randomized comparison
will reveal whether a single half-day training of GPs in the
management of HF and the practical appliance of an up-
titration scheme results in subsequent improvements in
functionality, HRQoL, and uptake of HF medication com-
pared to care as usual. In addition, cost-effectiveness will
be examined. We expect that our diagnostic-therapeutic
strategy is easy applicable and implementable, and above
all, is able to detect a large number of patients with previ-
ously unrecognized HF in primary care and optimize their
treatment, resulting in increased functional capacity and
HRQoL.
Regulation statement
This study is conducted according to the principles of
the current version of the declaration of Helsinki and in
accordance with the Dutch law on Medical Research
Involving Human Subjects Act (WMO).Ethics committee approval
The study was approved by the medical ethical commit-
tee (METC) of the University Medical Center Utrecht,
the Netherlands.
Additional file
Additional file 1: Initiation- and up-titration scheme for patient
with newly, screen-detected HF. Scheme handed to participating GPs
to facilitate easy initiation and up-titration of heart failure medication in
patients with newly, screen-detected HF. Also includes contra-indications
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